CN-122012707-A - CX43 as detection target and application of treatment target in lung adenocarcinoma

Abstract

The invention discloses application of CX43 as a detection target and a treatment target in lung adenocarcinoma, which proves that the cell gap junction channel protein CX43 can be used as a multifunctional biomarker and a treatment target in lung adenocarcinoma for the first time, wherein the expression level of the cell gap junction channel protein CX43 is positively correlated with clinical stages of tumors, can assist in stage diagnosis, has the functions of promoting the growth of the tumors, can remarkably inhibit the growth of the tumors in vivo aiming at gene knockout or drug inhibition of the CX43, and meanwhile, the high expression of the CX43 is remarkably correlated with the poor prognosis of non-small cell lung cancer patients. Therefore, CX43 provides a new target and strategy for diagnosis, prognosis evaluation and treatment of lung adenocarcinoma.

Inventors

• LIU HAIPENG
• JIANG XIAOFENG
• XU JUNFANG
• WANG YAXUAN
• NIU QIANPING

Assignees

• 上海市肺科医院（上海市职业病防治院）

Dates

Publication Date

20260512

Application Date

20260121

Claims (9)

1. 1. Use of an agent for detecting CX43 expression level for the preparation of a product for aiding in lung adenocarcinoma staging.
2. 2. The use according to claim 1, wherein the product detects the expression level of CX43 by immunohistochemistry or real-time fluorescent quantitative PCR.
3. Use of a cx43 inhibitor for the manufacture of a medicament for the treatment of lung adenocarcinoma.
4. 4. The use according to claim 3, wherein the CX43 inhibitor is a nucleic acid molecule capable of reducing the expression of the CX43 gene or is a peptide inhibitor capable of inhibiting the function of the CX43 channel.
5. 5. The use according to claim 4, wherein the nucleic acid molecule is sgRNA targeting CX43 gene, the nucleotide sequence of which is shown as SEQ ID No.1 or/and SEQ ID No.2, and the peptide inhibitor is GAP26.
6. 6. A pharmaceutical composition for treating lung adenocarcinoma, comprising the sgRNA or GAP26 of claim 5, and a pharmaceutically acceptable carrier.
7. 7. Use of a reagent for detecting CX43 expression in the manufacture of a product for assessing prognosis in a patient with non-small cell lung cancer.
8. 8. The use according to claim 7, wherein the product is obtained by detecting the expression level of CX43, wherein a high expression of CX43 is associated with a poor prognosis for the patient.
9. 9. The use according to claim 7, wherein the product detects the expression level of CX43 by immunohistochemistry or real-time fluorescent quantitative PCR.

Description

CX43 as detection target and application of treatment target in lung adenocarcinoma Technical Field The invention relates to the technical field of biological medicines, in particular to application of CX43 serving as a detection target and a treatment target in lung adenocarcinoma. Background Lung cancer is a major cause of cancer-related death worldwide, and its incidence continues to rise, becoming a major public health problem. Non-small cell lung cancer (NSCLC) is the most prominent pathological type in lung cancer, while lung adenocarcinoma is the most common subtype in NSCLC. Since the course of lung cancer is often hidden, early diagnosis presents a significant challenge, and many patients are already in mid-to-late stages when diagnosed, losing the opportunity for radical surgical resection, resulting in poor overall prognosis. Accurate staging and effective treatment are critical to improving prognosis in patients with lung adenocarcinoma. At present, for lung adenocarcinoma, especially early lung adenocarcinoma, high-sensitivity and high-specificity molecular markers still lack for accurate stage and prognosis evaluation clinically, and meanwhile, development of new therapeutic targets is also urgently needed. The search for biomarkers which can assist in staging, predict prognosis and serve as potential therapeutic intervention targets has important significance in improving the clinical management level of lung adenocarcinoma and the survival rate of patients. Disclosure of Invention The invention aims at overcoming the defects in the prior art and providing application of CX43 serving as a detection target and a treatment target in lung adenocarcinoma. In order to achieve the above purpose, the technical scheme adopted by the invention is as follows: in a first aspect, there is provided the use of an agent for detecting the amount of CX43 expressed in the preparation of a product for aiding in the staging of lung adenocarcinoma. Further, the product detects the expression level of CX43 by immunohistochemistry or real-time fluorescent quantitative PCR. In a second aspect, there is provided the use of a CX43 inhibitor for the manufacture of a medicament for the treatment of lung adenocarcinoma. Further, the CX43 inhibitor is a nucleic acid molecule capable of reducing CX43 gene expression or a peptide inhibitor capable of inhibiting CX43 channel function. Furthermore, the nucleic acid molecule is sgRNA targeting CX43 gene, the nucleotide sequence of the sgRNA is shown as SEQ ID No.1 or/and SEQ ID No.2, and the peptide inhibitor is GAP26. In a third aspect, a pharmaceutical composition for treating lung adenocarcinoma is provided, the sgRNA or GAP26 described above, and a pharmaceutically acceptable carrier. In a fourth aspect, there is provided the use of an agent for detecting CX43 expression in the preparation of a product for assessing the prognosis of a patient with non-small cell lung cancer. Further, the product is achieved by detecting the expression level of CX43, wherein high expression of CX43 correlates with a poor prognosis for the patient. Further, the product detects the expression level of CX43 by immunohistochemistry or real-time fluorescent quantitative PCR. Compared with the prior art, the invention has the following technical effects: The invention proves that the cell gap junction channel protein CX43 can be used as a multifunctional biomarker and a treatment target point in lung adenocarcinoma for the first time, the expression level of the cell gap junction channel protein CX43 is positively correlated with clinical stage of tumor, can assist stage diagnosis, has the functions of being necessary for promoting tumor growth, can remarkably inhibit tumor growth in vivo by aiming at gene knockout or drug inhibition of CX43, and meanwhile, the high expression of CX43 is remarkably correlated with poor prognosis of non-small cell lung cancer patients. Therefore, CX43 provides a new target and strategy for diagnosis, prognosis evaluation and treatment of lung adenocarcinoma. Drawings FIG. 1 is a photograph of the immunohistochemical staining of CX43 in example 1. FIG. 2 shows the relative expression levels of CX43 mRNA in various staged lung adenocarcinoma tissues in example 2. FIG. 3 is a graph of tumor tissue and tumor volume curve in example 3. FIG. 4 is a graph of tumor tissue and tumor volume curve in example 4. FIG. 5 is a graph of tumor tissue and tumor volume curve in example 5. FIG. 6 is a Kaplan-Meier survival curve in example 6. Detailed Description The invention is further described below with reference to the drawings and specific examples, which are not intended to be limiting. It should be noted that, without conflict, the embodiments of the present invention and features of the embodiments may be combined with each other. The experimental methods, in which specific conditions are not noted in the following examples, are generally conducted under conventional condit